pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

72 catalysts · 20 phase 2 completion · 11 phase 1 completion · 9 phase 2 initiation · 5 phase 1 2 completion · 5 phase 0 trial completion · 5 phase 3 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 75 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: ophthalmology×TA: cardiology×TA: pulmonology×from 2017-04-18×clear all
type
  • phase 2 completion20
  • phase 1 completion11
  • phase 2 initiation9
  • phase 1 2 completion5
  • phase 0 trial completion5
phase 3 initiation
5
  • filing5
  • phase 1 initiation4
  • phase iv trial initiation2
  • phase 3 completion2
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    22
    ›Apr 30, 2026phase 1 completion103d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

    Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

    full page →undisclosed Covid-19 vaccine →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

    full page →enoxaparin sodium biosimilar →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

    Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

    full page →DAPAGLIFLOZIN →source: globaldata
    ›Apr 30, 2026phase 1 2 completion103d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

    Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

    full page →deferiprone →source: globaldata
    ›Apr 30, 2026phase 1 2 completion103d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

    Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

    full page →Atibuclimab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion103d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

    full page →MK-8748 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion103d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

    Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

    full page →M-701 →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

    Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

    full page →dupilumab →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

    Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

    full page →polyphenol-rich cocoa extract →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

    Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

    full page →centhaquine citrate →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

    Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

    full page →lenvatinib →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

    Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

    full page →apixaban ODT →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →ephedrine →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

    Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

    full page →metformin hydrochloride ER →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →tozorakimab →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoCurtin University — influenza vaccine (Phase II Trial Completion)influenza vaccine

    Therapy area: Cardiovascular. Indication: Myocardial Infarction

    full page →influenza vaccine →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

    full page →ghrelin →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Respiratory. Indication: Cough

    full page →LIDOCAINE →source: globaldata
    ← prev
    page 2 of 2
    next →
    $MRK130.92+1.82%
    $AZN161.91+0.30%